Genmab stock heads into the open after a 10.80 percent year gain

At the close on September 22, 2026, Genmab stock traded at DKK 2,244.00 on Nasdaq Copenhagen and was up 10.80 percent year to date. The Bank of America healthcare conference featured Genmab on September 22.

Genmab stock closed at DKK 2,244.00 on Nasdaq Copenhagen on September 22, 2026. The shares had gained 10.80 percent since January 1, 2026, by the cited market update.

September 22, 2026 in numbers

Genmab A/S (ISIN DK0010272202) traded at DKK 2,244.00 on its primary Nasdaq Copenhagen market at 3:28 p.m. on September 22, 2026. The session update said the shares closed at that level, while Investing.com reported that Genmab outlined its late-stage oncology pipeline at the Bank of America Global Healthcare Conference on September 22, 2026.

The September 22 market value was 10.80 percent above the January 1, 2026 level. The same session saw the Nasdaq Composite close at 27,244.28, up 0.45 percent, providing a dated comparison with the broader US technology market.

September 23, 2026 outlook

Newsquawk reported on September 22, 2026, that three crucial Genmab readouts remained on track for the fourth quarter of 2026. That company-specific development is the main dated item heading into the September 23, 2026 session.